Peptide-protein interactions are characterized by the binding of peptides to large, often shallow pockets on protein surfaces without significantly altering the protein conformation. These interactions are typically stabilized by hydrogen bonds and interactions with key residues, enriching the interface with hydrophobic and aromatic residues reminiscent of the protein’s core (LifeTein Peptide). This understanding is crucial for designing peptide-based inhibitors that can precisely target and modulate specific PPIs, offering a strategic approach to drug development.

The design of peptide-based inhibitors often involves identifying and targeting conserved protein domains that recognize short linear peptide motifs. This approach benefits from the structural diversity and flexibility of peptides, allowing them to adopt various conformations for optimal binding. Domains such as SH2, PTB, SH3, and WW domains recognize specific motifs, offering a blueprint for designing peptides that can interfere with these interactions. Despite the challenge posed by the similarity between recognized sequences, structural insights into protein-peptide interactions have facilitated the development of selective peptide drugs.

The advancement in computational tools and structural biology has significantly impacted the design of protein-targeting peptides. Increased availability of crystallographic structures of protein complexes has paved the way for rational drug design, enabling the identification of crucial interaction sites and the development of peptides that can target these sites to modulate biological pathways effectively. Combinatorial approaches, such as phage display, peptide arrays, and peptide aptamers, complement rational design by identifying high-affinity peptide sequences through screening.

Furthermore, the self-assembly and molecular recognition properties of peptides extend their application beyond drug development to the creation of supramolecular biomaterials. These materials harness the self-organizing capacity of peptides to form structures that can interact with biological systems in a controlled manner, opening new avenues for drug delivery, tissue engineering, and the development of novel therapeutics (MDPI).

In the context of cancer research, peptides targeting PPIs present a promising strategy for developing novel therapeutic agents. The modulation of PPIs involved in oncogenic pathways, tumor suppression, and immune evasion mechanisms can provide targeted interventions with potentially high specificity and lower toxicity compared to conventional chemotherapy. The continuous improvement of computational and experimental methodologies is expected to enhance further the discovery and development of peptide-based PPI modulators with optimal properties for clinical application (Frontiers in Science).

Overall, the field of peptide-mediated modulation of protein-protein interactions is rapidly advancing, offering promising strategies for therapeutic development against a wide range of pathologies, including cancer. The synergy between computational design, structural biology, and experimental screening methods is critical to unlocking the full therapeutic potential of peptides in targeting complex biological interactions.

Wash the beads with 20 mM imidazole buffer, then elute with a gradient from 20 mM to 250 mM at 1mL/min over 30 min. With this method, I saw three contaminants that eluted at the same time as my protein: one with higher molecular weight, two with lower molecular weights. I changed the gradient to run for 60 min but obtained the same three contaminants. The contaminants begin eluting just prior to my protein, and complete their elution during the middle of my protein peak.

Wash the beads twice with 20 mM buffer, then elute with the same gradient described previously over the course of 30 min. With this protocol, I saw the same three contaminants eluting together with my protein, causing me to lose some of the protein.

Wash the beads at 20 mM, followed by another wash step at 40 mM, then run the usual elution gradient over the course of 30 min. In this case, I saw the same three contaminants again and lost even more of my protein.

Wash the beads with 50 mM buffer before eluting with the same gradient described. 80% of my protein was eluted, but it was accompanied by 100% of the contaminants. To separate the protein, I collected the 80% protein plus its accompanying contaminants in a 45 mL volume. I used dialysis to remove the imidazole and made a batch contact. Then I eluted three times with 1 mL 250 mM imidazole buffer each and found that 95% of my protein remained on the beads. At the end of this protocol, I got very little of my protein, but at least it was pure. However, solving the purity problem came at a high price in terms of quantity. My final yield was 0.3 mg from a 500 mL cell culture. I used 50 mM sodium phosphate and 500 mM NaCl with varying levels of imidazole for the buffers.

Can anyone offer suggestions for eliminating the contaminants while maintaining my protein? Additionally, I wonder why my protein elutes at such low imidazole concentrations (around 40 mM)? And in test protocol (iv) described above, why won’t my protein elute from the beads?

It looks like the contaminants are interacting with the His-tag on your protein, causing it to elute at 40 mM imidazole. You could try to eliminate this interaction by using 6M urea in all your buffers.

I would like to do some structural studies with my protein, so I don’t think it is possible for me to use urea.
You can remove the urea by dialysis after you purify the protein. Urea is only a mild denaturant, so your protein should be able to refold into the original structure.
Why don’t you add another purification step? Size exclusion might work well depending on the exact sizes of the contaminants. In my experience, proteins at that expression level don’t come clean with only one step.

I recommend using cobalt-loaded resin or Sigma His-Select, both of which I’ve found to have higher specificity.
In my experience, one Ni column seldom returns a pure protein. You can try ion exchange or gel filtration to further purify your protein.
I faced the same problem last year and was able to solve it using a His-tag purification kit from Thermo Scientific. You might try that kit as well.
I purify N-terminally His-tagged membrane proteins using Talon-cobalt columns under denaturing conditions (6 M Gu-Hcl to Urea) and my protein elutes at 0.5 mM-1 mM imidazole. There is a small yield, but it is quite pure. After that, I renature the protein by dialyzing it slowly in descending concentrations of urea, eventually ending with PBS. Since you are interested in the structural analysis but not the function of the protein, you can purify the protein under denaturing conditions suggested and later renature the protein.

Why does my protein lose its activity following affinity purification? I can partially purify my protein with Ni-His tag affinity chromatography, but activity assays show no activity. As a positive control, I used another pure protein of the same class that acts on the same substrate, so I don’t believe the problem is with the assay reagents or technique. Why don’t I see any activity? Could this be caused by co-purified products?

Did you use urea in the elution buffer? If so, did you refold the eluted protein? Are you certain that the His-tag doesn’t interfere with the conformation of the protein? Your protein may be denatured or incorrectly folded following purification. Many proteins coordinate around zinc or another metal, so you may need to add some metal ions for full activity. Another possibility is that the high level of imidazole used to elute the protein from the affinity column may inhibit the activity of your protein. You can test this by adding some of the eluted protein to your positive control.

My protein is His(6X)-tagged and purified without urea. The buffer is Tris-HCl (pH7.2) and the activity of the positive control is not affected by high imidazole concentrations. There appears to be a product corresponding to the activity of the positive control protein in my test protein assays, despite running them in separate assay tubes. I tested all the buffers, cofactors (Mg and Mn), and reagents for contamination with the control protein, but there does not appear to be any contamination. Is it possible that two proteins in the same class react differently to differing levels of imidazole?

You should try reducing the imidazole concentration in your eluted protein to determine if that is causing the loss of activity. Did you assay the activity of your protein prior to applying it to the Ni-column? The His-tag may be influencing the conformation of the protein. If this is the case, you will need to move the His-tag to the other terminus. You could also try removing the imidazole from your purified protein by dialysis prior to testing for activity.